GE Healthcare has signed an agreement with Affibody to collaborate on the development of a Her2-targeted PET imaging agent, which is scheduled to begin clinical trials later this year.

On the heels of Amyvid's June 1 release on the U.S. market, Cardinal Health announced it will manufacture and distribute Eli Lilly's new diagnostic imaging agent that aids in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.

Eli Lilly and Avid Radiopharmaceuticals, a wholly owned subsidiary of Lilly, have announced that Amyvid is available to imaging centers in markets surrounding 16 manufacturing sites. To coincide with the availability of Amyvid, Lilly is also announcing the launch of their reader training program.

Physicians and patients who want to track the safety of pharmaceuticals in Europe have a new resource with the launch of a public website. Reports published on the site are derived from EudraVigilance, the drug safety database used by European Union regulators to monitor benefits and risks of a medicine once it has been approved.

ViewRay has received FDA 510(k) premarket notification clearance for its MRI-guided radiation therapy system.

Philips Healthcare has made wireless portable detector-sharing functionality available on its static and mobile DR and DR/fluoroscopy equipment, allowing hospitals to use one detector on multiple DR modalities.

With our June 1 newsletter, healthimaging.com debuts its Best Of newsletter. Each week our editorial team will review the weeks stories and compile the top five or six for our readers to revisit.

The U.S. House of Representatives has reauthorized the Medical Device User Fee & Modernization Act, and done so with a resoundingly bipartisan 387 to five vote.